AVICANNA INC (AVCN.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:AVCN - CA05368K1003 - Common Stock
AVCN.CA Key Statistics, Chart & Performance
The current stock price of AVCN.CA is 0.23 CAD. In the past month the price increased by 4.55%. In the past year, price decreased by -26.98%.
AVCN.CA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to AVCN.CA. When comparing the yearly performance of all stocks, AVCN.CA is a bad performer in the overall market: 92.27% of all stocks are doing better.
AVCN.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AVCN.CA. AVCN.CA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
AVCN.CA Financial Highlights
Over the last trailing twelve months AVCN.CA reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 77.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.87% | ||
| ROE | -60.37% | ||
| Debt/Equity | 0 |
AVCN.CA Forecast & Estimates
AVCN.CA Ownership
AVCN.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.95 | 3.84B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 1.59B | ||
| CRON.CA | CRONOS GROUP INC | 24.4 | 1.40B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 7.16 | 887.82M | ||
| DHT-U.CA | DRI HEALTHCARE TRUST | 5.12 | 634.32M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 630.07M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 593.75M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 562.00M | ||
| TSND.CA | TERRASCEND CORP | N/A | 423.49M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 16.91 | 394.76M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 331.70M | ||
| HITI.CA | HIGH TIDE INC | N/A | 314.10M |
Related stock screener links
About AVCN.CA
Company Profile
Avicanna, Inc. is a medical cannabis company, which intends to engage in the business of discovery and development processes, intellectual property portfolio, strategic relationships, and cultivation infrastructure. The company is headquartered in Toronto, Ontario. The company went IPO on 2019-07-18. The company focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. The company has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.
Company Info
AVICANNA INC
480 University Avenue, Suite 1502
TORONTO ONTARIO M5G 1V2 CA
CEO: Aras Azadian
Employees: 38
Phone: 16472435283
AVICANNA INC / AVCN.CA FAQ
What does AVICANNA INC do?
Avicanna, Inc. is a medical cannabis company, which intends to engage in the business of discovery and development processes, intellectual property portfolio, strategic relationships, and cultivation infrastructure. The company is headquartered in Toronto, Ontario. The company went IPO on 2019-07-18. The company focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. The company has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.
Can you provide the latest stock price for AVICANNA INC?
The current stock price of AVCN.CA is 0.23 CAD.
Does AVICANNA INC pay dividends?
AVCN.CA does not pay a dividend.
How is the ChartMill rating for AVICANNA INC?
AVCN.CA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of AVICANNA INC (AVCN.CA) based on its PE ratio?
AVICANNA INC (AVCN.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.02).
Would investing in AVICANNA INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AVCN.CA.
What is the next earnings date for AVCN stock?
AVICANNA INC (AVCN.CA) will report earnings on 2026-03-30, after the market close.